AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00843388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet 25 mg OD
Study NCT01816061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental - COMPASS
Description: Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
Study NCT01816061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - COMPASS
Description: Increased hours of patient-provider interactions Group.
Study NCT01086020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
Study NCT01086020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin plus ezetimibe
Description: Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
Study NCT03070470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 1500 mg orally two times per day for 2.5 days
Study NCT03070470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
Study NCT03070470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
Study NCT03070470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
Study NCT03070470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (administered orally)
Study NCT03070470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dofetilide and Diltiazem
Description: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Study NCT02589899 — intervention group
Intervention type: OTHER
Intervention: Needle placement in different tissue types
Description: Bioimpedance will be measured for needle positions in different tissue types
Study NCT01671111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184AQ
Description: Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or active form)
Study NCT02801656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Oral, encapsulated FMT
Study NCT02801656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin po 125 mg qid x 10 days
Study NCT02801656 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation Placebo
Description: Matching placebo to FMT
Study NCT02801656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Placebo
Description: Matching placebo to Vancomycin
Study NCT04503304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: already included in arm/group descriptions.
Study NCT04503304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: already included in arm/group descriptions.
Study NCT00530270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
Study NCT00530270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
Study NCT01989312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous cannulation.
Description: A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
Study NCT01989312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.
Description: Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.
Study NCT01989312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous cannulation.
Description: A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
Study NCT01989312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine ASA monitoring
Description: Monitorization with ECG, noninvasive blood pressure and spO2.
Study NCT01989312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premedication midazolam
Description: Premedication with 0.03 mg/kg midazolam iv
Study NCT01989312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT01989312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Study NCT01989312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Study NCT03863600 — intervention group
Intervention type: BEHAVIORAL
Intervention: Midwife-led continuity of care
Description: Midwives from governmental hospitals provide antenatal and postnatal case-load-care in rural villages governmental clinics
Study NCT04384562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: A 20 mg methylphenidate (Ritalin®) is administered only once for the dopamine reuptake inhibitor group.
Study NCT04384562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine
Description: A 4 mg reboxetine (Edronax®) is administered only once for the noradrenaline reuptake inhibitor group.
Study NCT04384562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: A 2 mg nicotine (Nicorette®) gum is administered only once for the cholinergic receptor agonist group.
Study NCT04384562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: A placebo pill is administered only once.
Study NCT04384562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: A placebo pill is administered only once.
Study NCT04384562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gum
Description: A placebo gum is administered only once.
Study NCT04384562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gum
Description: A placebo gum is administered only once.
Study NCT04142775 — intervention group
Intervention type: OTHER
Intervention: complication versus no complication
Description: development of ICH
Study NCT03589599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored tobacco
Description: Effects of flavored tobacco
Study NCT03589599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-flavored tobacco
Description: Effects of non-flavored tobacco
Study NCT04200053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology massage
Description: Before the burn dressing, a reflexology massage will be performed for 20 minutes on the right foot and 20 minutes on the left foot. This intervention will continue in the morning for 3 days.
Study NCT04200053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology massage and passive music
Description: Before the burn dressing, a reflexology massage and passive music will be performed for 20 minutes on the right foot and 20 minutes on the left foot. Instrumental music will be played during the massage. This intervention will continue in the morning for 3 days.
Study NCT02011282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days
Study NCT02543463 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trident X3 Insert with Navigation system
Study NCT02543463 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trident X3 Insert with conventional instrumentation
Study NCT01041482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib 400mg twice daily
Study NCT00428142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375mg/m2 day 1
Study NCT00428142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3mg/m2 days 1 \& 8
Study NCT00428142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750mg/m2 day 1
Study NCT00428142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40mg/m2 days 1-5
Study NCT00428142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4mg/m2 day 1 (dose capped at 2mg)
Study NCT01328951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
Study NCT01328951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
Study NCT01328951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
Study NCT01328951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second-Line Chemotherapy
Description: Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
Study NCT03972787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive social robot
Description: ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
Study NCT02162836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
Study NCT03483142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: ( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
Study NCT03483142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: ( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol
Study NCT03331055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENS
Description: percutaneous electrical nerve stimulation
Study NCT03331055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: transcutaneous electrical nerve stimulation
Study NCT01197521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily
Study NCT01197521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily/150 mg once daily
Study NCT01197521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, fostamatinib
Description: Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
Study NCT03705637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: * Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~* The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~  o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~* Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation.
Study NCT00562952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan, Bisoprolol
Description: Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
Study NCT00562952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no intervention
Study NCT00711620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: 1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
Study NCT00711620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thymosin alpha 1
Description: 1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
Study NCT03085524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet function testing
Description: The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
Study NCT03085524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vascular ultrasonography
Description: The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
Study NCT03200366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored DVD
Description: A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed.
Study NCT03200366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: Participants talk by telephone with a Patient Navigator who is a trained nurse. The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content. The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
Study NCT04564742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg tablets given once daily, per oral use
Study NCT04564742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
Study NCT01396174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prosocial online support group
Description: Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
Study NCT01396174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Online Support Group
Description: Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
Study NCT02081040 — intervention group
Intervention type: OTHER
Intervention: Not applicable (observational study with no active intervention)
Study NCT01785459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
Study NCT01785459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: 10 mg Intravenous injection of Prochlorperazine
Study NCT00501371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS
Description: soft-gel capsule, 15 mg/cap., Qd, 12 weeks
Study NCT00501371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soft-gel capsule, Qd, 12 weeks
Study NCT04278209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 1
Description: Participant will receive Breakfast 1
Study NCT04278209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 2
Description: Participant will receive Breakfast 2
Study NCT04278209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participant will receive water
Study NCT03295877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7171009
Description: Patients will receive RO7171009 via ITV injection.
Study NCT01568398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Study NCT02692365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance + hemodynamic + infusion of gadolinium
Study NCT01390272 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Booster/ low resource
Description: A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
Study NCT01390272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster/ low resource
Description: A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
Study NCT01390272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium/Level 1 resource intensity
Description: Monthly tailored RN delivered calls + home BP monitoring.
Study NCT01390272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High/Level 2 resource intensity
Description: Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
Study NCT00596661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriMaxx Coronary Stent placement
Description: Angioplasty with coronary artery stent placement
Study NCT01072305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Description: Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
Study NCT01072305 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IPC - placebo
Description: ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.